David Malcom Rodman Sells 6,349 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 6,349 shares of the firm’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $23.93, for a total value of $151,931.57. Following the completion of the sale, the insider directly owned 63,443 shares in the company, valued at approximately $1,518,190.99. The trade was a 9.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

• On Wednesday, June 10th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $25.00, for a total value of $54,250.00.
• On Monday, May 18th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.55, for a total value of $11,488.35.
• On Tuesday, May 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $29.36, for a total value of $186,377.28.
• On Wednesday, May 13th, David Malcom Rodman sold 14,056 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $28.58, for a total value of $401,720.48.
• On Monday, May 11th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $29.71, for a total value of $64,500.41.
• On Friday, April 17th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $31.33, for a total value of $13,033.28.
• On Wednesday, April 15th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.66, for a total value of $175,585.68.
• On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.54, for a total value of $373,099.32.
• On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.38, for a total value of $59,414.60.

Mineralys Therapeutics Stock Down 1.3%

NASDAQ:MLYS opened at $23.62 on Friday. The business’s 50-day moving average price is $27.83 and its two-hundred day moving average price is $30.61. Mineralys Therapeutics, Inc. has a twelve month low of $12.59 and a twelve month high of $47.65. The stock has a market cap of $1.95 billion, a P/E ratio of -11.52 and a beta of 0.57.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.04. On average, equities research analysts expect that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MLYS has been the topic of a number of research reports. Jefferies Financial Group reissued a “hold” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Tuesday, April 21st. Bank of America raised their price objective on Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a report on Friday, March 13th. TD Cowen initiated coverage on Mineralys Therapeutics in a report on Monday, April 27th. They set a “buy” rating on the stock. Finally, Wall Street Zen cut Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Mineralys Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $49.33.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of large investors have recently modified their holdings of the company. AQR Capital Management LLC purchased a new position in Mineralys Therapeutics in the 1st quarter worth approximately $550,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Mineralys Therapeutics by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after purchasing an additional 702 shares during the period. Goldman Sachs Group Inc. increased its stake in Mineralys Therapeutics by 166.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock worth $4,739,000 after purchasing an additional 186,480 shares during the period. Woodline Partners LP purchased a new position in Mineralys Therapeutics in the 1st quarter worth approximately $757,000. Finally, Creative Planning purchased a new position in Mineralys Therapeutics in the 2nd quarter worth approximately $336,000. 84.46% of the stock is owned by hedge funds and other institutional investors.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.